RNA-Triggered Chromatin Shredding Hits Cancer's Hardest Targets.

RNA-triggered chromatin shredding using Cas12a2 selectively eliminates tumor cells with mutations in critical cancer genes like TP53 and MYC in mouse models.

• Why it matters: Targeting mutations that have resisted traditional therapies is crucial for developing effective cancer treatments, especially for aggressive or drug-resistant tumors.
• What they did: Researchers activated Cas12a2 in mouse models by targeting specific transcripts, enabling the enzyme to shred chromatin and kill tumor cells harboring these mutations.
• The result: This approach demonstrates a promising new strategy to attack difficult-to-treat cancers by precisely destroying cells with resistant genetic alterations.